Aortic Valve Stenosis Clinical Trial
Official title:
A Prospective, Multi-center, Single-arm Clinical Investigation for Evaluation of the Safety and Effectiveness of the MicroPort™ CardioFlow VitaFlow™ Transcatheter Aortic Valve System in the Treatment of Severe Aortic Stenosis
Verified date | November 2020 |
Source | Shanghai MicroPort CardioFlow Medtech Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a pre-market clinical investigation aiming to evaluate the safety and effectiveness of MicroPort™ CardioFlow VitaFlow™ Transcatheter Aortic Valve System for the treatment of severe aortic stenosis.
Status | Active, not recruiting |
Enrollment | 120 |
Est. completion date | December 31, 2021 |
Est. primary completion date | September 6, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 70 Years and older |
Eligibility | Inclusion criteria : Enrollment was limited to patients who met all of the following criteria: 1. Age = 70 years old(Phase II)/Age =18 years old,male or female who are not pregnant (Phase I); 2. Patients have severe aortic stenosis: Mean gradient> 40mmHg(1mmHg = 0.133kPa), or peak velocity> 4m/s, or an aortic valve area(AVA) <1.0 cm² (or AVA index <0.6 cm²/m²); 3. NYHA classification = II; 4. Life expectancy> 12 months; 5. Anatomically suitable for transcatheter aortic valve implantation; 6. Assessed by a multidisciplinary heart team as a patient unsuitable for surgical aortic valve replacement; 7. Patients who can understand the purpose of the investigation, volunteer to participate in and sign the informed consent form, and are willing to comply with relevant examinations and follow-up visits. Exclusion criteria: 1. Acute myocardial infarction occurred within 30 days before the treatment; 2. Patients with congenital unicuspid aortic valve or aortic root anatomy and lesions that are not suitable for transcatheter valve implantation; 3. Any therapeutic heart surgery within 30 days; 4. Mixed aortic valve disease(aortic stenosis with severe regurgitation); moderate and severe mitral stenosis; severe mitral regurgitation; severe tricuspid regurgitation; 5. Blood dyscrasia, including neutropenia (WBC < 3 × 10^9/L), acute anemia(HB <90 g/L), thrombocytopenia(PLT <50 × 10^9/L), hemorrhagic constitution, and coagulopathy disease; 6. Untreated coronary artery disease requiring revascularization; 7. Hemodynamic instability requiring systolic support or mechanical heart assistance; 8. Need for emergency surgery for any reason; 9. Obstructive hypertrophic cardiomyopathy; 10. Severe left ventricular dysfunction, left ventricular ejection fraction(LVEF) < 20%; severe pulmonary hypertension and right ventricular dysfunction; 11. Echocardiography suggests the presence of intracardiac masses, thrombi, or neoplasms; 12. Active peptic ulcer or history of upper gastrointestinal bleeding within 3 months; 13. Allergy to aspirin, heparin, ticlopidine, clopidogrel, nitinol, or contrast agents; 14. Cerebrovascular events including transient ischemic attack(TIA) occurred within 6 months; 15. Renal insufficiency decompensation(end creatinine clearance < 20ml/min), and / or end-stage renal disease require long-term dialysis treatment; 16. Vascular diseases affecting device access; 17. Active infectious endocarditis or other active infection; 18. Participated in clinical investigations of other drugs or medical devices before the election, and had not completed the primary endpoint; 19. The investigator judged that the patient had poor compliance and could not complete the study as required. |
Country | Name | City | State |
---|---|---|---|
China | Fuwai Hospital | Beijing | Beijing |
China | West China Hospital of Sichuan University | Chengdu | Sichuan |
China | The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou | Zhejiang |
China | Zhongshan Hospital Fudan University | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai MicroPort CardioFlow Medtech Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of device success-Phase I | at immediate post-procedure | ||
Primary | All-cause mortality at 12 months post implantation-Phase II | at 12 months post-procedure | ||
Secondary | Rate of major adverse events -Phase I | at 30 days post implantation | ||
Secondary | Hemodynamic performance-Phase II | Hemodynamic performance, including the mean prosthetic valve gradient(in mmHg), the Effective orifice(in cm^2), and the degree of prosthetic valve regurgitation measured by transthoracic echocardiography (TTE) | at immediate post-procedure, discharge, 30 days, 6 months, 1 year and annually up to 5 years post implantation | |
Secondary | Heart function(NYHA)-Phase II | at immediate post-procedure, discharge, 30 days, 6 months, 1 year and annually up to 5 years post implantation | ||
Secondary | Rate of safety events according to VARC2-Phase II | at immediate, 30 days, 1 year and annually up to 5 years post implantation | ||
Secondary | Rate of major cardiovascular and cerebrovascular events(MACCE)-Phase II | at immediate, 30 days, 1 year and annually up to 5 years post implantation | ||
Secondary | Rate of balloon pre-dilatation success-Phase II | at immediate post implantation | ||
Secondary | Rate of balloon post-dilatation success-Phase II | at immediate post implantation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03186339 -
Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI
|
||
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Terminated |
NCT02854319 -
REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System
|
N/A | |
Recruiting |
NCT05601453 -
The ReTAVI Prospective Observational Registry
|
||
Withdrawn |
NCT05481814 -
CPX in Paradoxical Low Flow Aortic Stenosis
|
||
Completed |
NCT02241109 -
Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity
|
N/A | |
Completed |
NCT01700439 -
Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve
|
N/A | |
Recruiting |
NCT04429035 -
SLOW-Slower Progress of caLcificatiOn With Vitamin K2
|
N/A | |
Completed |
NCT04103931 -
Impact of a Patient Decision Aid for Treatment of Aortic Stenosis
|
N/A | |
Completed |
NCT03950440 -
Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement
|
||
Active, not recruiting |
NCT02661451 -
Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)
|
N/A | |
Completed |
NCT02758964 -
Evaluation of Cerebral Thrombembolism After TAVR
|
||
Completed |
NCT02792452 -
Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis
|
||
Completed |
NCT02847546 -
Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation
|
N/A | |
Not yet recruiting |
NCT02536703 -
Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population
|
Phase 3 | |
Not yet recruiting |
NCT02541877 -
Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve
|
Phase 3 | |
Completed |
NCT02249000 -
BIOVALVE - I / II Clincial Investigation
|
N/A | |
Not yet recruiting |
NCT02221921 -
Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI
|
N/A | |
Active, not recruiting |
NCT02080299 -
Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation
|
Phase 2 | |
Terminated |
NCT01939678 -
Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease
|